Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirfenidone - Roche

Next Previous
Drug Profile

Pirfenidone - Roche

Alternative Names: AMR-69; Deskar; Esbriet; Etuary; F-647; Pirespa; RG-6062; RO-0220912; S-7701; S-770108

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KDL Gmbh; Marnac
  • Developer AFT Pharmaceuticals; Beijing Continent Pharmaceutical; Il Dong; InterMune; Justus Liebig University Giessen; National Institute for Health Research; Roche; Shanghai Genomics; Shionogi; Stanford University; University of California at San Francisco; University of Liverpool; University of Manchester
  • Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis
  • Preregistration Interstitial lung diseases
  • Phase II Acute lung injury; Heart failure; Lung transplant rejection; Pulmonary fibrosis
  • Phase I Diabetic nephropathies
  • Clinical Phase Unknown SARS-CoV-2 acute respiratory disease
  • No development reported Graft-versus-host disease
  • Discontinued Glomerulonephritis; Multiple sclerosis; Peritoneal fibrosis; Renal fibrosis; Retinal disorders; Scleroderma

Most Recent Events

  • 05 Jul 2023 Pirfenidone is still in phase I trials for Diabetic nephropathies in China (GNI Pharma pipeline, July 2023)
  • 31 Dec 2022 Roche Pharma completes a Clinical trials in SARS-COV-2 acute respiratory disease (In Adults, In the elderly) in Israel (PO) (NCT04653831)
  • 16 Nov 2022 Genentech completes the phase II trial in Interstitial lung diseases (in patients with pulmonary fibrosis) in USA (PO) (NCT04461587)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top